This enzyme was previously identified as a priority drug target, as DGAT1 mutant mice are viable and show numerous beneficial metabolic characteristics such as resistance to diet-induced obesity and increased insulin or leptin sensitivity (Smith et al., 2000). The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.